We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Stenting Superior to Angioplasty for Peripheral Artery Disease

By HospiMedica International staff writers
Posted on 07 Nov 2012
Among patients with atherosclerotic popliteal artery stenosis, primary stenting with a nitinol stent may be superior to balloon angioplasty, according to a new study.

Researchers at the Albert-Ludwigs-University (Freiburg, Germany) and Heart Center Bad Krozingen (Freiburg, Germany) enrolled 246 patients in the prospective, multicenter, randomized Endovascular Treatment of Atherosclerotic Popliteal Artery Lesions (ETAP) trial, assigning 119 patients to receive the Bard Peripheral Vascular (Tempe, AZ, USA) Lifestent and 127 to balloon angioplasty; the average lesion length was 41 mm in the stent group and 43 mm in controls. More...
The mean stenosis diameter of the popliteal artery was 93% among those patients assigned to stenting, and 92% among those who were treated with the balloon.

The results showed that a year after treatment, 67.4% of the patients who received the stent had patent popliteal arteries, compared with 44.9% of patients treated with balloon angioplasty. Stent fractures occurred twice during the study. Other outcomes at 12 months were similar for death, heart attack, amputation, and ankle brachial index, but 49 of the patients undergoing angioplasty required repeat treatment compared with 15 of those getting stents. Absolute walking distances reflected an increase of 70 meters in the balloon group and 116 meters among the stented patients. The study was presented at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, held during October 2012 in Miami (FL, USA).

“The popliteal artery is considered as a 'no stent' zone due to potential excessive external forces applied to the stent in the popliteal fossa,” said lead author and study presenter associate Prof. Thomas Zeller, MD, chief physician at the Heart Center Bad Krozingen. “Results from this trial indicate that treatment of popliteal artery obstructive lesions with a nitinol self-expanding stent is safe. Additionally, one-year primary patency and target lesion revascularization rates were substantially better with the nitinol stent than with balloon angioplasty.”

The Lifestent vascular stent system uses advanced helical struts and angled bridges to withstand high bending, compression, and torsion forces, thus allowing dynamic vessel conformity and a low fracture rate.

Related Links:

Albert-Ludwigs-University
Heart Center Bad Krozingen
Bard Peripheral Vascular



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.